Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

COMPLETED RESEARCH: CLINICAL/TRANSLATIONAL RESEARCH
Abstract #CT10

Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Clinical Trials, Leukemia, Lymphoma

Presenter: Nilanjan Ghosh, MD, PhD, Chief, Lymphoma Division, Levine Cancer Institute, Atrium Health, Charlotte, NC

Co-Authors: Jacqueline C. Barrientos, MD, MS, Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY; Jeff P. Sharman, MD, Willamette Valley Cancer Institute & Research Center, Eugene, OR; Danielle Brander, MD, Duke University Health System, Durham, NC; Meghan Gutierrez, Lymphoma Research Foundation, New York, NY; Karen Kadish, APRN-BC, MSN, OCN, Tufts Medical Center, Boston, MA; Israel Arango Hisijara, MD, Pharmacyclics, an AbbVie Company, Sunnyvale, CA; Sandhya Upasani, MS, Pharmacyclics, an AbbVie Company, Sunnyvale, CA; Jennifer Han, PharmD, Janssen Scientific Affairs, Horsham, PA; Qing Huang, Janssen Scientific Affairs, Horsham, PA; Reethi Iyengar, PhD, Pharmacyclics, an AbbVie Company, Sunnyvale, CA; Anthony R. Mato, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Background: The informCLL registry is the largest prospective, US-based observational registry of patients who received treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the era of novel agents.

Objective: To report baseline characteristics, prognostic biomarker testing, and treatment patterns in routine clinical practice for patients enrolled in the informCLL registry.

Methods: From October 2015 to June 2019, the informCLL registry enrolled eligible patients aged ≥18 years with CLL or SLL who had initiated FDA-approved treatment for CLL or SLL within ≥45 days of enrollment. Based on the index treatment at enrollment, patients were classified into 5 groups: ibrutinib (single-agent or combination), chemoimmunotherapy, chemotherapy, immunotherapy, and other novel agents.

Results: The informCLL registry enrolled 1461 patients; 855 (59%) patients were treatment-naïve and 606 (41%) had relapsed or refractory disease; the median age was 71 years, 64% of the patients were male, and 88% had ECOG performance status of 0/1. For patients with staging performed (N = 852), 51% had Rai stage III/IV. Most (93%) enrolling sites were community-based practices. The median time from diagnosis to index treatment for untreated patients was 18.6 months and 84.27 months for patients with relapsed or refractory disease. The median follow-up was 14.9 months for untreated patients and 15.3 months for patients with relapsed or refractory disease. Overall, prognostic biomarker testing was infrequent: fluorescence in situ hybridization testing was performed in 28% of patients, testing for TP53 mutation in 11%, and testing for IGHV mutation was 12%. Of patients who had prognostic biomarker testing, 24% (100/415) had deletion 17p, 27% (43/162) had TP53 mutation, and 71% (121/171) had wild-type IGHV. Overall, the most common treatment was ibrutinib (46%), and 87% started ibrutinib at the recommended dose of 420 mg daily. For patients continuing ibrutinib therapy, 75% did not require dose modifications. At 12 months or 24 months, 77% (307/401) and 68% (126/184) of patients continued ibrutinib therapy, respectively. For patients who completed chemoimmunotherapy regimens, bendamustine plus rituximab (BR) and fludarabine, cyclophosphamide, and rituximab (FCR) were the most common chemoimmunotherapy regimens received; 80% and 85% of patients who received BR and FCR, respectively, received <6 cycles. Only 6% of patients had index treatment of other novel agents.

Conclusion: Results from the informCLL registry allow for a prospective assessment of CLL treatment patterns in the era of novel agents. Ibrutinib was the most common index treatment received, and most ibrutinib-treated patients continued therapy at 2 years of follow-up; 33% of patients received chemoimmunotherapy. Prognostic biomarker testing was infrequent, especially for TP53 and IGHV mutational status, indicating that prognostic marker testing results may not always guide treatment selection for patients with high-risk disease.

Related Items
Pyrexia Management in Patients with Melanoma Treated with Dabrafenib/Trametinib Combination Therapy
August 2022 Clinical Trials to Clinical Practice published on August 23, 2022 in Clinical Trials, Melanoma
Evaluation of Clinical Pharmacy Services for Phase 1 Clinical Trials
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Original Article, Clinical Trials, Oncology Pharmacy Protocols
Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Lymphoma, CAR T-Cell Therapy
Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia
Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia, Pediatric Cancer
Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, CAR T-Cell Therapy, Lymphoma
Hepatitis B Virus Infection Monitoring in Patients with Lymphoma Receiving Anti-CD20 Monoclonal Antibodies
Christopher Sinoimeri, PharmD, Bryan Do, PharmD, BCOP, Sheree Chen, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in Original Article, Lymphoma, Immunotherapy, Infections
Arsenic Trioxide–Induced QTc Interval Prolongation and the Potential Benefit of Beta-Blockers in Patients with Acute Promyelocytic Leukemia: Case Series
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in Case Reports, Leukemia, Adverse Events
Second-Line Axicabtagene Ciloleucel Therapy Improves Outcomes in Patients with Large B-Cell Lymphoma: ZUMA-7
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Lymphoma, CAR T-Cell Therapy
HOP(A) Springs Eternal
Bryna Delman Ewachiw, PharmD, BCOP, Mark L. Zangardi, PharmD, BCOP
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in Editorial, HOPA Abstracts
Copyright © The Lynx Group, LLC. All rights reserved.